Understanding how immune cell changes contribute to diabetes and autoimmune conditions
Alterations of leukocyte integrin signaling leading to diabetes and autoimmunity
This research explores how specific changes in immune cells might lead to type 1 diabetes and other autoimmune diseases.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11135443 on NIH RePORTER |
What this research studies
This project looks at how changes in a specific gene, called SKAP2, affect immune cells and might cause type 1 diabetes and other autoimmune conditions. Researchers found a unique change in the SKAP2 gene in a patient with type 1 diabetes, which makes their immune cells stickier than usual. We want to understand how this stickiness impacts the immune system and contributes to the development of these diseases. This work could help us learn more about the root causes of these conditions.
Who could benefit from this research
Good fit: Patients with type 1 diabetes and other autoimmune conditions, especially those with a family history or unique genetic profiles, are the focus of this research.
Not a fit: Patients whose conditions are not related to immune cell signaling or genetic factors explored in this specific pathway may not directly benefit from this particular research.
Why it matters
Potential benefit: If successful, this work could uncover new ways to understand and potentially treat type 1 diabetes and related autoimmune conditions by targeting specific immune cell behaviors.
How similar studies have performed: While genetic links between SKAP2 and type 1 diabetes have been identified, the specific mechanisms by which SKAP2 alterations lead to autoimmune type 1 diabetes are currently unknown, making this a novel area of investigation.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Anderson, Mark S — University of California, San Francisco
- Study coordinator: Anderson, Mark S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.